查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1298765

2023-2028年按疾病類型（活動性肺結核、潛伏性肺結核和其他）、診斷和治療（診斷、治療）、終端用戶（醫院、專科診所、家庭護理和其他）和地區分類的抗結核治療藥物市場

Anti-Tuberculosis Therapeutics Market by Disease Type (Active TB, Latent TB, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Specialty Clinics, Homecare, and Others), and Region 2023-2028
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3個工作天內

價格

2022年，全球抗結核治療劑的市場規模達到13.5479億美元。展望未來，IMARC Group預計，到2028年，市場規模將達到19.9134億美元，在2023-2028年期間表現出6.70%的成長率（CAGR）。不斷成長的醫療支出、有利的報銷政策、技術進步和不斷成長的公私合作關係代表了推動市場發展的一些關鍵因素。

抗結核治療藥物是指用於管理結核病（TB）的藥物和治療策略，結核病是由結核分枝桿菌引起的細菌感染。結核病主要影響肺部，也可擴散到身體的其他部位，如腎臟、脊柱和大腦。抗結核治療法用於從體內消滅細菌並防止感染擴散。這是通過聯合使用抗生素來實現的，這些抗生素通常要開六到九個月。一些最常用的藥物包括異煙肼、利福平、乙胺丁醇和吡嗪醯胺。具體使用的藥物組合取決於感染的嚴重程度和病人的健康狀況。此外，定期監測和隨訪對於確保治療成功和防止耐藥結核病的發生也是至關重要的。近年來，抗結核治療劑獲得了牽引力，因為它還涉及支持性護理，如氧氣治療、營養支持和可能出現的併發症管理。

抗結核治療劑的市場趨勢：

推動市場發展的主要因素之一是全球結核病（TB）的高發病率，特別是在中低收入國家。此外，由於治療不徹底、醫療基礎設施不足以及缺乏適當的醫療服務，耐藥性結核病的發生率越來越高，這對市場的成長產生了積極的影響。除此之外，新藥和治療策略的開發也在推動抗結核治療劑市場的發展。近年來，一些新藥，如貝達喹啉和德拉馬尼，已被批准用於治療結核病。與傳統的結核病藥物相比，這些藥物具有更好的療效和安全性。與此相呼應，技術和診斷的進步使結核病的早期檢測和診斷成為可能，從而導致及時開始治療和更好的病人結果，這代表了另一個主要的成長誘導因素。此外，醫療保健支出的增加，特別是在新興經濟體，已經導致醫療保健基礎設施的改善，增加了獲得高品質醫療保健的機會，包括結核病治療。除此之外，人們對結核病的認知不斷提高，以及早期診斷和治療的重要性，也使抗結核病療法的需求升級。此外，政府對結核病控制項目的計劃和資助在推動抗結核病治療劑市場方面發揮了重要作用。例如，政府和非政府組織（NGO）正在合作，以提高意識，改善診斷，並確保獲得負擔得起的有效治療，這預計將在未來幾年內推動市場成長。

本報告中回答的關鍵問題：

  • 迄今為止，全球抗結核治療劑市場的表現如何，未來幾年將如何表現？
  • 全球抗結核治療劑市場的驅動因素、限制因素和機會是什麼？
  • 每個驅動因素、限制因素和機會對全球抗結核治療劑市場的影響是什麼？
  • 哪些是關鍵的區域市場？
  • 哪些國家代表著最具吸引力的抗結核治療劑市場？
  • 基於疾病類型的市場細分是什麼？
  • 在抗結核治療劑市場中，哪種疾病類型最有吸引力？
  • 基於診斷和治療的市場細分是什麼？
  • 在抗結核治療劑市場中，哪種診斷和治療方法最具吸引力？
  • 基於終端用戶的市場詳細情形是怎樣的？
  • 哪個是抗結核治療劑市場中最有吸引力的終端用戶？
  • 全球抗結核治療劑市場的競爭結構是什麼？
  • 誰是全球抗結核治療劑市場的主要參與者/公司？

目錄

第一章：前言

第二章：範圍和方法

  • 研究的目標
  • 利益相關者
  • 數據來源
    • 主要來源
    • 二級來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第三章：執行摘要

第四章：簡介

  • 概述
  • 主要行業趨勢

第五章：全球抗結核病治療藥物市場

  • 市場概況
  • 市場表現
  • COVID-19的影響
  • 市場預測

第六章：按疾病類型分類的市場

  • 活動性肺結核
    • 市場趨勢
    • 市場預測
  • 潛伏性肺結核
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第7章：按診斷和治療分類的市場

  • 診斷
    • 市場趨勢
    • 關鍵領域
      • 血液測試
      • 影像學檢查
      • 痰液檢測
      • 其他
    • 市場預測
  • 治療
    • 市場趨勢
    • 關鍵領域
      • 一線藥物
      • 主要類型
      • 異煙肼
      • 乙胺丁醇
      • 利福平
      • 其他
      • 二線藥物
      • 主要類型
      • 硫氰酸酯(Thiacetazone)
      • 對氨基水楊酸(PAS)
      • 其他藥物
      • 其他類型
    • 市場預測

第八章：按終端用戶分類的市場

  • 醫院
    • 市場趨勢
    • 市場預測
  • 專科診所
    • 市場趨勢
    • 市場預測
  • 家庭護理
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第九章：按地區分類的市場

  • 北美洲
    • 美國
      • 市場趨勢
      • 市場預測
    • 加拿大
      • 市場趨勢
      • 市場預測
  • 亞太地區
    • 中國
      • 市場趨勢
      • 市場預測
    • 日本
      • 市場趨勢
      • 市場預測
    • 印度
      • 市場趨勢
      • 市場預測
    • 韓國
      • 市場趨勢
      • 市場預測
    • 澳大利亞
      • 市場趨勢
      • 市場預測
    • 印尼
      • 市場趨勢
      • 市場預測
    • 其他國家
      • 市場趨勢
      • 市場預測
  • 歐洲
    • 德國
      • 市場趨勢
      • 市場預測
    • 法國
      • 市場趨勢
      • 市場預測
    • 英國
      • 市場趨勢
      • 市場預測
    • 義大利
      • 市場趨勢
      • 市場預測
    • 西班牙
      • 市場趨勢
      • 市場預測
    • 俄羅斯
      • 市場趨勢
      • 市場預測
    • 其他國家
      • 市場趨勢
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場趨勢
      • 市場預測
    • 墨西哥
      • 市場趨勢
      • 市場預測
    • 其他國家
      • 市場趨勢
      • 市場預測
  • 中東和非洲
    • 市場趨勢
    • 按國家分類的市場
    • 市場預測

第十章：驅動因素、限制因素和機會

  • 概述
  • 驅動因素
  • 限制因素
  • 機會

第十一章：價值鏈分析

第十二章：波特五力分析

  • 概述
  • 買方的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第十三章：價格分析

第十四章：競爭格局

  • 市場結構
  • 主要參與者
  • 主要參與者的簡介
    • F. Hoffmann-La Roche Ltd.
    • Lannett Company Inc.
    • Lupin Limited
    • Macleods Pharmaceuticals Limited
    • Otsuka Pharmaceutical Co. Ltd

請注意，這只代表部分公司的名單，完整的名單已在報告中提供。

Product Code: SR112023A7629

The global anti-tuberculosis therapeutics market size reached US$ 1,354.79 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,991.34 Million by 2028, exhibiting a growth rate (CAGR) of 6.70% during 2023-2028. The rising healthcare spending, favorable reimbursement policies, technological advancements, and growing public-private partnerships represent some of the key factors driving the market.

Anti-tuberculosis therapeutics refer to the drugs and treatment strategies used to manage tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. TB primarily affects the lungs and can also spread to other parts of the body, such as the kidneys, spine, and brain. Anti-tuberculosis therapeutics are used to eradicate the bacteria from the body and prevent the spread of the infection. This is achieved through a combination of antibiotics that are typically prescribed for six to nine months. Some of the most commonly used drugs include isoniazid, rifampin, ethambutol, and pyrazinamide. The exact combination of drugs used depends on the severity of the infection and the patient's health status. In addition, regular monitoring and follow-up are also essential to ensure treatment success and prevent the development of drug-resistant TB. In recent years, anti-tuberculosis therapeutics have gained traction as it also involves supportive care, such as oxygen therapy, nutrition support, and management of complications that may arise.

Anti-Tuberculosis Therapeutics Market Trends:

One of the primary factors driving the market is the high prevalence of tuberculosis (TB) worldwide, particularly in low- and middle-income countries. Additionally, the growing incidence of drug-resistant TB due to incomplete treatment, inadequate healthcare infrastructure, and lack of access to appropriate healthcare is positively influencing the market growth. Other than this, the development of new drugs and treatment strategies is also driving the anti-tuberculosis therapeutics market. In recent years, several new drugs, such as bedaquiline and delamanid, have been approved for the treatment of TB. These drugs offer improved efficacy and safety profiles compared to traditional TB drugs. In line with this, advancements in technology and diagnostics have enabled early detection and diagnosis of TB, leading to timely initiation of treatment and better patient outcomes, which represents another major growth-inducing factor. Furthermore, the increase in healthcare spending, particularly in emerging economies, has led to improved healthcare infrastructure and increased access to quality healthcare, including TB treatment. Apart from this, the growing awareness about TB and the importance of early diagnosis and treatment has also escalated the demand for anti-tuberculosis therapeutics. Moreover, government initiatives and funding for TB control programs have played a significant role in driving the anti-tuberculosis therapeutics market. For instance, governments and non-governmental organizations (NGOs) are working together to increase awareness, improve diagnosis, and ensure access to affordable and effective treatments, which is expected to drive market growth in the upcoming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global anti-tuberculosis therapeutics market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on the disease type, diagnosis and treatment, and end user.

Disease Type Insights:

Active TB

Latent TB

Others

The report has provided a detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the disease type. This includes active TB, latent TB, and others.

Diagnosis and Treatment Insights:

Diagnosis

Blood Tests

Imaging Tests

Sputum Tests

Others

Treatment

First-Line of Drugs

Isoniazid

Ethambutol

Rifampin

Others

Second-Line of Drugs

Thiacetazone

Paraaminosalicyclic Acid (PAS)

Others

Others

A detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the diagnosis and treatment has also been provided in the report. This includes diagnosis (blood tests, imaging tests, sputum tests, and others), treatment (first-line of drugs (isoniazid, ethambutol, rifampin, and others) second-line of drugs (thiacetazone, paraaminosalicyclic acid (PAS), and others), and others

End User Insights:

Hospitals

Specialty Clinics

Homecare

Others

The report has provided a detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the end user. This includes hospitals, specialty clinics, homecare, and others.

Regional Insights:

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for anti-tuberculosis therapeutics. Some of the factors driving the North America anti-tuberculosis therapeutics market included rising prevalence of tuberculosis, growing drug resistance, and numerous government initiatives.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global anti-tuberculosis therapeutics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include F Hoffmann-La Roche Ltd., Lannett Company Inc., Lupin Limited, Macleods Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global anti-tuberculosis therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global anti-tuberculosis therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global anti-tuberculosis therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive anti-tuberculosis therapeutics market?
  • What is the breakup of the market based on the disease type?
  • Which is the most attractive disease type in the anti-tuberculosis therapeutics market?
  • What is the breakup of the market based on the diagnosis and treatment?
  • Which is the most attractive diagnosis and treatment in the anti-tuberculosis therapeutics market?
  • What is the breakup of the market based on end user?
  • Which is the most attractive end user in the anti-tuberculosis therapeutics market?
  • What is the competitive structure of the global anti-tuberculosis therapeutics market?
  • Who are the key players/companies in the global anti-tuberculosis therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Anti-Tuberculosis Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease Type

  • 6.1 Active TB
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Latent TB
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Diagnosis and Treatment

  • 7.1 Diagnosis
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Blood Tests
      • 7.1.2.2 Imaging Tests
      • 7.1.2.3 Sputum Tests
      • 7.1.2.4 Others
    • 7.1.3 Market Forecast
  • 7.2 Treatment
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 First-Line of Drugs
      • 7.2.2.1.1 Major Types
      • 7.2.2.1.1.1 Isoniazid
      • 7.2.2.1.1.2 Ethambutol
      • 7.2.2.1.1.3 Rifampin
      • 7.2.2.1.1.4 Others
      • 7.2.2.2 Second-Line of Drugs
      • 7.2.2.2.1 Major Types
      • 7.2.2.2.1.1 Thiacetazone
      • 7.2.2.2.1.2 Paraaminosalicyclic Acid (PAS)
      • 7.2.2.2.1.3 Others
      • 7.2.2.3 Others
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Homecare
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 F. Hoffmann-La Roche Ltd.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 SWOT Analysis
    • 14.3.2 Lannett Company Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Lupin Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Macleods Pharmaceuticals Limited
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Otsuka Pharmaceutical Co. Ltd
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Anti-Tuberculosis Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017-2022
  • Figure 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 4: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Disease Type (in %), 2022
  • Figure 5: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Diagnosis and Treatment (in %), 2022
  • Figure 6: Global: Anti-Tuberculosis Therapeutics Market: Breakup by End User (in %), 2022
  • Figure 7: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Anti-Tuberculosis Therapeutics (Active TB) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Anti-Tuberculosis Therapeutics (Active TB) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Anti-Tuberculosis Therapeutics (Treatment) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Anti-Tuberculosis Therapeutics (Treatment) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Anti-Tuberculosis Therapeutics (Homecare) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Anti-Tuberculosis Therapeutics (Homecare) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: North America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: North America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: United States: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: United States: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Canada: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Canada: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Asia-Pacific: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Asia-Pacific: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: China: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: China: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Japan: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Japan: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: India: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: India: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: South Korea: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: South Korea: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Australia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Australia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Indonesia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Indonesia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Europe: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Europe: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Germany: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Germany: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: France: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: France: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: United Kingdom: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: United Kingdom: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Italy: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Italy: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Spain: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Spain: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Russia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Russia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Latin America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Latin America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Brazil: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Brazil: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Mexico: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Mexico: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Breakup by Country (in %), 2022
  • Figure 74: Middle East and Africa: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Global: Anti-Tuberculosis Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 76: Global: Anti-Tuberculosis Therapeutics Industry: Value Chain Analysis
  • Figure 77: Global: Anti-Tuberculosis Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Anti-Tuberculosis Therapeutics Market: Key Industry Highlights, 2022 & 2028
  • Table 2: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Disease Type (in Million US$), 2023-2028
  • Table 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Diagnosis and Treatment (in Million US$), 2023-2028
  • Table 4: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 5: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Anti-Tuberculosis Therapeutics Market: Competitive Structure
  • Table 7: Global: Anti-Tuberculosis Therapeutics Market: Key Players